Bioincyte converts traditional platelet-rich plasma to platelet-rich fibrin matrix, eliminating extensive contamination of red and white blood cells. Bioincyte converts the PRP through a controlled process that protects and preserves platelets.
It creates a long-lasting environment for platelets to release growth factors. PRFM has several advantages over traditional PRP, including an ability to retain more growth factors, less trauma caused to individual blood cells and controlled time-release abilities.
The Bioincyte system allows patients to be treated in a variety of settings in a matter of minutes, according to a Feb. 14 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
